Home » Stocks » Sorrento Therapeutics

Sorrento Therapeutics, Inc. (SRNE)

Stock Price: $14.42 USD 0.81 (5.95%)
Updated Aug 7, 2020 4:00 PM EDT - Market closed
After-hours: $14.48 +0.06 (0.42%) Aug 7, 7:59 PM

Stock Price Chart

Key Info

Market Cap 3.49B
Revenue (ttm) 35.54M
Net Income (ttm) -270.17M
Shares Out 242.03M
EPS (ttm) -1.64
PE Ratio n/a
Forward PE 2.41
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Aug 7, 2020
Last Price $14.42
Previous Close $13.61
Change ($) 0.81
Change (%) 5.95%
Day's Open 13.09
Day's Range 13.07 - 15.04
Day's Volume 62,392,529
52-Week Range 1.39 - 15.04

More Stats

Market Cap 3.49B
Enterprise Value 3.64B
Earnings Date (est) n/a
Ex-Dividend Date n/a
Shares Outstanding 242.03M
Float 168.19M
EPS (basic) -1.58
EPS (diluted) -1.64
FCF / Share -0.75
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 50.08M
Short Ratio 1.96
Short % of Float 23.63%
Beta 3.25
PE Ratio n/a
Forward PE 2.41
P/FCF Ratio n/a
PS Ratio 98.20
PB Ratio 24.30
Revenue 35.54M
Operating Income -176.75M
Net Income -270.17M
Free Cash Flow -162.85M
Net Cash -151.45M
Net Cash / Share -0.63
Gross Margin -246.72%
Operating Margin -497.34%
Profit Margin -760.20%
FCF Margin -458.22%
ROA -20.42%
ROE -443.24%
ROIC -44.60%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (2)

Buy 2
Overweight 0
Hold 0
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

$27.00*
(87.24% upside)
Low
24.0
Current: $14.42
High
30.0
Target: 27.00
*Average 12-month price target from 2 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Year2019201820172016201520142013201220112010
Revenue31.4321.191528.154.593.830.460.580.530.68
Revenue Growth48.31%-86.04%1762.81%77.6%20%731.52%-21.23%10.36%-22.47%-
Gross Profit19.2014.131487.342.641.780.460.580.530.68
Operating Income-259-15025.34-96.78-74.01-34.74-21.67-4.85-3.24-1.81
Net Income-292-2049.13-60.92-45.81-34.66-21.91-4.85-3.24-1.81
Shares Outstanding13310669.7450.3636.9126.6815.0511.419.928.83
Earnings Per Share-2.35-1.920.13-1.21-1.24-1.30-1.46-0.42-0.25-0.25
Operating Cash Flow-173-112-99.18-70.93-42.07-28.76-16.49-3.80-2.74-1.55
Capital Expenditures-11.44-11.20-10.97-6.86-3.71-0.59-0.42-0.55-1.05-0.05
Free Cash Flow-184-123-110-77.79-45.78-29.36-16.91-4.35-3.80-1.59
Cash & Equivalents80.7721320.8783.5013671.9031.675.093.475.28
Total Debt2912335.2147.329.2312.154.81---
Net Cash / Debt-210-19.9615.6636.1912759.7626.865.093.475.28
Assets55862443240234414292.586.784.575.69
Liabilities52541722531520332.8325.770.580.360.60
Book Value78.5920920080.0414510966.816.204.215.08
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Sorrento Therapeutics, Inc.
Country United States
Employees 310
CEO Henry H. Ji

Stock Information

Ticker Symbol SRNE
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: SRNE

Description

Sorrento Therapeutics, Inc., a clinical stage biopharma company, develops therapies for cancer, autoimmune, inflammatory, and neurodegenerative diseases. It operates through two segments, Sorrento Therapeutics and Scilex. The company provides cancer therapeutics by leveraging its proprietary G-MAB antibody library and targeted delivery modalities, which include chimeric antigen receptor T-cell therapy (CAR-T), dimeric antigen receptor T-cell therapy, and antibody drug conjugates, as well as bispecific antibody approaches. It also offers Sofusa, a drug delivery technology that delivers biologics directly into the lymphatic system. In addition, the company's clinical programs in development include anti-CD38 CAR-T therapy for the treatment of multiple myeloma, as well as for amyloidosis and graft-versus-host diseases. Further, it develops resiniferatoxin, a non-opioid-based TRPV1 agonist neurotoxin for late stage cancer and osteoarthritis knee pain treatment; and ZTlido, a lidocaine delivery system for the treatment of postherpetic neuralgia. Additionally, the company engages in the development of SEMDEXA, an injectable viscous gel formulation, which is Phase III trial for the treatment of sciatica, a pathology of low back pain; and SP-103, an investigational non-aqueous lidocaine topical system undergoing clinical development in chronic low back pain conditions. It has various collaborations with SmartPharm Therapeutics Inc. to develop gene-encoded antibody vaccine to protect against COVID-19; Celularity, Inc. for initiating Phase I/II clinical study, including up to 86 patients with COVID-19; and Mount Sinai Health System to develop COVI-SHIELD, an antibody therapy targeting SARS-CoV-2 infection, as well as a research testing agreement with The University of Texas Medical Branch at Galveston for the preclinical testing of Sorrento's COVID-19 therapeutic product candidates. The company was founded in 2006 and is based in San Diego, California.